RecruitingPhase 2NCT06212102

Dydrogesterone Versus GnRH Antagonist in Poor Responders Undergoing Double Ovarian Stimulation

Dydrogesterone Versus GnRH Antagonist in Poor Responders Undergoing Double Ovarian Stimulation: A Randomized Controlled Non-inferiority Trial

Sponsor

Bedaya Hospital

Enrollment

120 participants

Start Date

May 8, 2024

Study Type

INTERVENTIONAL

Conditions

Infertility

Summary

The aim of this randomized controlled trial is to compare the efficacy and cost-effectiveness of using progestin with GnRH antagonist to prevent premature LH surge in poor responders undergoing double stimulation protocol.

Eligibility

Sex: FEMALEMin Age: 35 YearsMax Age: 44 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called GnRH antagonist and a drug called Progestin primed ovarian stimulation for people with infertility. The study is currently recruiting participants at 2 locations. People eligible for this study include women aged 35 Years to 44 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGProgestin primed ovarian stimulation

HMG ( 300IU) was used during the follicular phase of ovarian stimulation (FPS) and during the luteal phase of ovarian stimulation (LPS). Progestin (dydrogesterone) 30 mg/day was used to prevent premature LH surge during the FPS and LPS.

DRUGGnRH antagonist

HMG ( 300IU) was used during the follicular phase of ovarian stimulation (FPS) and during the luteal phase of ovarian stimulation (LPS). Flexible GnRH antagonist protocol (Cetrorelix acetate) (0.2 mg) was used to prevent premature LH surge during the FPS and LPS.